Literature DB >> 22697003

Late development of malignant fibrous histiocytoma at the site of a giant cell tumour 38 years after initial surgery.

Keiichi Muramatsu1, Koichiro Ihara, Tomoyuki Miyoshi, Yasuhiro Kawakami, Daisuke Nakashima, Toshihiko Taguchi.   

Abstract

The authors report on a patient who developed a malignant fibrous histiocytoma at the site of a benign giant cell tumour, which had been treated by curettage 38 years previously. This latency period is, to their knowledge, the longest yet reported. This female patient was initially treated for a benign giant cell tumour of the proximal tibia when she was 33 years old; she underwent curettage and Kiel bone grafting. She had not received radiation therapy. Twenty eight years later, she underwent a second operation due to recurrence of a tumour. No specific histological diagnosis was possible: histology suggested a benign tumour, however compatible with a low-grade malignant potential but not associated with giant cell tumour. The patient underwent a third operation, with extensive curettage and total knee arthroplasty 38 years after the initial surgery, because of progressive knee pain. Postoperative histopathology study showed high-grade malignant fibrous histiocytoma. Finally, she underwent above-knee amputation because of uncontrollable progression of the tumour. The use of xenogenic bone graft, bone cement and associated bone necrosis potentially contributed to the development of a malignant tumour adjacent to the primary giant cell tumour.

Entities:  

Mesh:

Year:  2012        PMID: 22697003

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  1 in total

1.  Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy.

Authors:  Eiji Nakata; Hotaka Kawai; Tomohiro Fujiwara; Toshiyuki Kunisada; Hirofumi Inoue; Mashu Futagawa; Haruyoshi Katayama; Takuto Itano; Toshifumi Ozaki
Journal:  Oncol Lett       Date:  2022-07-19       Impact factor: 3.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.